Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alnylam Pharmaceuticals stock | 131.05

Own Alnylam Pharmaceuticals stock in just a few minutes.


Fact checked

Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,323 staff and has a trailing 12-month revenue of around USD$345.2 million.

How to buy shares in Alnylam Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Alnylam Pharmaceuticals. Find the stock by name or ticker symbol: ALNY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alnylam Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$131.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alnylam Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Alnylam Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Alnylam Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Alnylam Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$131.05, which is 0.02% up on its pre-crash value of USD$131.03 and 54.23% up on the lowest point reached during the March crash when the shares fell as low as USD$84.97.

If you had bought USD$1,000 worth of Alnylam Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$863.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,142.76.

Alnylam Pharmaceuticals share price

Use our graph to track the performance of ALNY stocks over time.

Alnylam Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$131.05
52-week range USD$84.97 - USD$167.33
50-day moving average USD$135.9794
200-day moving average USD$139.4904
Wall St. target price USD$163.78
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-8.254

Buy Alnylam Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alnylam Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alnylam Pharmaceuticals price performance over time

Historical closes compared with the close of $131.05 from 2020-11-16

1 week (2020-11-17) 1.35%
1 month (2020-10-27) 3.34%
3 months (2020-08-25) -2.27%
6 months (2020-05-23) N/A
1 year (2019-11-25) 16.57%
2 years (2018-11-23) 78.69%
3 years (2017-11-24) -1.35%
5 years (2015-11-25) 24.51%

Alnylam Pharmaceuticals financials

Revenue TTM USD$345.2 million
Gross profit TTM USD$194.7 million
Return on assets TTM -18.95%
Return on equity TTM -53.61%
Profit margin -245.14%
Book value $12.103
Market capitalisation USD$16.3 billion

TTM: trailing 12 months

Shorting Alnylam Pharmaceuticals shares

There are currently 3.3 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 9.1% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.

Alnylam Pharmaceuticals's "short interest ratio" (SIR)

Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 549621.92242833). Alnylam Pharmaceuticals's SIR currently stands at 5.93. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 5930 shares are currently held short.

However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0388% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 39 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.

Find out more about how you can short Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals share dividends

We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.

Alnylam Pharmaceuticals share price volatility

Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $84.97 up to $167.33. A popular way to gauge a stock's volatility is its "beta".

ALNY.US volatility(beta: 1.49)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.4892. This would suggest that Alnylam Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alnylam Pharmaceuticals overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site